Capricor Therapeutics (CAPR) Capital Expenditures (2011 - 2026)

Capricor Therapeutics' Capital Expenditures history runs 14 years deep, the most recent figure standing at $5.1 million for Q1 2026.

• In Q1 2026, Capital Expenditures rose 471.61% year-over-year to $5.1 million; the TTM figure through Mar 2026 stood at $7.1 million (up 390.28% YoY), while the FY2025 annual figure was $2.9 million, up 148.91% from the prior year.
• Capital Expenditures for Q1 2026 stood at $5.1 million, up from $1.7 million in the prior quarter.
• The five-year high for Capital Expenditures was $5.1 million in Q1 2026, with the low at $9145.0 in Q3 2024.
• The 5-year median for Capital Expenditures is $488798.0 (2024), against an average of $735584.9.
• The sharpest annual moves came in 2022 and 2024: Capital Expenditures soared 1437.75% in 2022, then plunged 96.61% in 2024.
• Capricor Therapeutics' Capital Expenditures stood at $694044.0 in 2022, then decreased by 19.51% to $558604.0 in 2023, then decreased by 12.5% to $488798.0 in 2024, then surged by 240.61% to $1.7 million in 2025, then surged by 207.63% to $5.1 million in 2026.
• Business Quant data shows CAPR's Capital Expenditures at $5.1 million in Q1 2026, $1.7 million in Q4 2025, and $55843.0 in Q3 2025.